<DOC>
	<DOCNO>NCT01579500</DOCNO>
	<brief_summary>The purpose study determine whether botulinum toxin A effective treatment neuropathic pain spinal cord injury patient .</brief_summary>
	<brief_title>Neuropathic Pain Study With Botulinum Toxin A Spinal Cord Injury Patients</brief_title>
	<detailed_description>Neuropathic pain remain significant cause life quality deterioration . This study include spinal cord injury patient refractory chronic neuropathic pain investigate whether injection botulinum toxin A improve pain score .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>twenty year age paraplegic tetraplegic due cervical thoracic spinal cord injury 12 month since spinal cord injury ASIA impairment scale unchanged 6 month persistence neuropathic pain three month remission recurrence neuropathic pain six month pain score 40mm visual analogue scale neuropathic pain cause confounding factor spinal cord injury contraindicate botulinum toxin type A change pain medication one month prior study enrollment condition involve neuromuscular junction ( Ex . Eaton Lambert disease , myasthenia gravis ) person receive botulinum toxin type A within three month prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>